Pfizer: Atrial Fibrillation trials
The registry lists 15 Atrial Fibrillation studies with Pfizer as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 2 1Phase 3 1Phase 4 1No phase 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in FranceCompletedNCT05838664Results posted
- Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of BleedingCompletedNCT05471505Results posted
- Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With MedicareCompletedNCT04681482Results posted
- Non-Interventional Study Describing Direct Costs Related to Anti-coagulation TreatmentCompletedNCT04435769Results posted
- Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In ColombiaCompletedNCT04234698Results posted
- Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in KoreaCompletedNCT03572972Results posted
- Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial FibrillationCompletedNCT03570047Results posted
- Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)CompletedNCT03441633Results posted
- Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)CompletedNCT02100228Phase 4Results posted
- A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial FibrillationCompletedNCT00787150Phase 2Results posted
- Atrial Fibrillation Data Linkage Non-Interventional StudyCompletedNCT05810727
- Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in BelgiumWithdrawnNCT05116267
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in FranceCompletedNCT05038228
- The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based StudyWithdrawnNCT04198844
- S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial FibrillationCompletedNCT00244426Phase 3